Compare UTHR & ASTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTHR | ASTS |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | United States | United States |
| Employees | N/A | 1126 |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1B | 25.4B |
| IPO Year | 1999 | N/A |
| Metric | UTHR | ASTS |
|---|---|---|
| Price | $524.48 | $69.20 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 8 |
| Target Price | ★ $567.57 | $72.10 |
| AVG Volume (30 Days) | 450.9K | ★ 16.8M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.07 | N/A |
| EPS | ★ 5.82 | N/A |
| Revenue | ★ $1,483,300,000.00 | N/A |
| Revenue This Year | $6.39 | $167.10 |
| Revenue Next Year | $14.18 | $391.80 |
| P/E Ratio | $92.05 | ★ N/A |
| Revenue Growth | ★ 2.38 | N/A |
| 52 Week Low | $272.18 | $39.50 |
| 52 Week High | $609.35 | $133.86 |
| Indicator | UTHR | ASTS |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 40.15 |
| Support Level | $517.59 | $66.05 |
| Resistance Level | $542.66 | $95.17 |
| Average True Range (ATR) | 13.06 | 6.39 |
| MACD | -1.23 | -0.79 |
| Stochastic Oscillator | 1.84 | 19.36 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
AST SpaceMobile Inc is currently designing, developing and manufacturing the constellation of BlueBird (BB) satellites and has begun launching its planned space-based Cellular Broadband network distributed through a constellation of low Earth orbit (LEO) satellites. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.